Gyre Therapeutics Inc(GYRE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:21 PM ET (Korea 10/31 06:21)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.2 | Insider Own | 77.69% | Shs Outstand | 106.0M | Perf Week | -22.14% |
| Market Cap | 0.48B | Forward P/E | - | EPS next Y | 41.25% | Insider Trans | -0.18% | Shs Float | 23.6M | Perf Month | -34.93% |
| Enterprise Value | 0.47B | PEG | - | EPS next Q | -0.12 | Inst Own | 4.64% | Short Float | 8.15% | Perf Quarter | -25.45% |
| Income | -0.02B | P/S | 4.05 | EPS this Y | -2100% | Inst Trans | 9.21% | Short Ratio | 15.81 | Perf Half Y | -41.6% |
| Sales | 0.12B | P/B | 4.48 | EPS next 5Y | - | ROA | -9.89% | Short Interest | 1.93M | Perf YTD | -35.48% |
| Book/sh | 1.02 | P/C | 6.46 | EPS past 3/5Y | -63.33% - | ROE | -15.66% | 52W High | -50.16% ($9.14) | Perf Year | -40.46% |
| Cash/sh | 0.71 | P/FCF | - | Sales past 3/5Y | 4.46% 40.96% | ROIC | -13.15% | 52W Low | -16.27% ($5.44) | Perf 3Y | -40.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -494.61% | Gross Margin | 94.3% | Volatility(W/M) | 15.21% 6.85% | Perf 5Y | -43.28% |
| Dividend TTM | - | EV/Sales | 3.93 | Sales Y/Y TTM | 16.83% | Oper. Margin | -11.41% | ATR (14) | 0.48 | Perf 10Y | -82.96% |
| Dividend Ex-Date | 2023/1/13 | Quick Ratio | 3.66 | EPS Q/Q | -5368.18% | Profit Margin | -15.47% | RSI (14) | 29.5 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.26 | Sales Q/Q | 8.72% | SMA20 | -29.01% ($6.41) | Beta | 2 | Target Price | $18.67 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/7 | SMA50 | -32.34% ($6.72) | Rel Volume | 3.23 | Prev Close | $6.41 |
| Employees | 625 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -111.64% 9.87% | SMA200 | -34.82% ($6.98) | Avg Volume(3M) | 0.12M | Price | $4.55 |
| IPO | 2006/4/12 | Option/Short | Yes/Yes | Trades | 2977 | Volume | 394,091 | Change | -28.94% |
🧬 Zayra Therapeutics is a biotech company developing anti-fibrotic new drugs targeting chronic organ fibrotic diseases. Centered on its lead candidate Hydronidone, the company is advancing clinical development and commercialization in the areas of liver fibrosis and metabolic dysfunction-associated steatohepatitis (MASH). The company is headquartered in the US and also operates a business based in the Chinese market.
Over the past 1 year, on the lower side
50% below its 1-year high.
Traded more than usual. That is 323% of its average volume.
GYRE has a sound balance sheet but weak earning power
Of every $100 in sales, $11.41 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -2100.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $405. Peers typically go for $1,268. It is about in line with its own 3-year average.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -43.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #219 of 597 in the industry
Based on market cap of $483M.
GYRE#219 Gyre Therapeutics Inc $483M PER - 
FTH#220 Faeth Therapeutics Inc $483M PER - 
RGNX#221 Regenxbio Inc $475M PER - 
INDP#222 Indaptus Therapeutics Inc $475M PER - 
MNPR#223 Monopar Therapeutics Inc $472M PER - 
FAQ
What kind of company is GYRE?
GYRE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GYRE?
The market cap of GYRE is approximately $483M, ranking 3,171 within its sector.
What is the 52-week high and low for GYRE?
GYRE has recorded a 52-week high of $9.14 and a low of $5.44.
